DRD2 and major depressive disorder: Another top finding from the TWAS analysis was DRD2 (D2 dopamine receptor) with a significantly predicted decreased expression in the nucleus accumbens, which is a drug target and critical part of the mesolimbic dopamine reward circuit that has long been implicated in depression.